Chaudhry Arslan, Biggiani Christopher, Afzal Muhammad, Chaudhry Sohail, Vwich Yazan
Internal Medicine, Saint Joseph's Regional Medical Center, Paterson, USA.
Endocrinology, Diabetes, and Metabolism, Saint Joseph's Regional Medical Center, Paterson, USA.
Cureus. 2021 Jun 26;13(6):e15949. doi: 10.7759/cureus.15949. eCollection 2021 Jun.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of medications utilized for the treatment of diabetes mellitus by mechanisms promoting incretin release and insulin production. Although poorly understood, cases of acute pancreatitis have been observed in patients taking GLP-1 RAs. Sodium-glucose co-transporter-2 inhibitors (SGLT-2is) are another class of diabetic medications inhibiting renal glucose reabsorption which have been associated with rare cases of euglycemic ketoacidosis. Acute pancreatitis itself has been an observable cause of diabetic ketoacidosis, although typically in a hyperglycemia state. In this case report, we present a patient on SGLT-2is and GLP-1 RAs who developed acute pancreatitis, which may have precipitated euglycemic diabetic ketoacidosis (eu-DKA).
胰高血糖素样肽-1受体激动剂(GLP-1 RAs)是一类通过促进肠促胰岛素释放和胰岛素生成机制来治疗糖尿病的药物。尽管对此了解甚少,但在服用GLP-1 RAs的患者中已观察到急性胰腺炎病例。钠-葡萄糖协同转运蛋白-2抑制剂(SGLT-2is)是另一类抑制肾脏葡萄糖重吸收的糖尿病药物,与罕见的正常血糖性酮症酸中毒病例有关。急性胰腺炎本身就是糖尿病酮症酸中毒的一个可观察到的病因,尽管通常处于高血糖状态。在本病例报告中,我们介绍了一名同时服用SGLT-2is和GLP-1 RAs并发生急性胰腺炎的患者,该胰腺炎可能引发了正常血糖性糖尿病酮症酸中毒(eu-DKA)。